Navigation Links
The Rett Syndrome Research Trust launches operations
Date:9/26/2008

. Our first five projects represent diverse yet complimentary approaches to treatment and reversal, encompassing drug screening, elucidation of target areas, and control of MECP2.

The projects include an international collaboration sponsored jointly with Autism Speaks and the Medical Research Council of the UK. The collaboration is based in the laboratory of Adrian Bird, Ph.D., at the University of Edinburgh, with key contributions from Nathaniel Heintz, Ph.D. of Rockefeller University. Professor Bird, who first isolated the MeCP2 protein in 1992, last year published his astonishing reversal of full-blown symptoms in a model of Rett Syndrome. He is the Buchanan Professor of Genetics at Edinburgh, and Deputy Chairman of the Wellcome Trust. Dr. Heintz is the James and Marilyn Simons Professor of Molecular Biology, and a Howard Hughes Medical Institute Investigator whose work involves identification of novel pathways that participate in the development, function and dysfunction of the mammalian brain. Dr. Heintz has pioneered a variety of advanced genetic tools that can be employed to understand the impact of Rett Syndrome on specific brain circuits. This collaboration will inform all potential translational research, whether through gene therapy, protein replacement or drug discovery.

"We are extremely pleased to be collaborating on this important effort. The exciting recent discoveries by Rett Syndrome researchers have energized the field. This collaboration will help sustain its momentum," says Geri Dawson, Chief Science Officer at Autism Speaks.

Huda Zoghbi, M.D. whose 1999 research breakthrough revealed that Rett Syndrome is caused by mutations in the MECP2 gene, is a key advisor to RSRT and Professor in the departments of Molecular and Human Genetics, Pediatrics, Neurology and Neuroscience at Baylor College of Medicine and a Howard Hughes Medical Institute Investigator. She is particularly interested in the growing number of cl
'/>"/>

Contact: Monica Coenraads
monica@rsrt.org
203-243-5733
Rett Syndrome Research Trust
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. 70 years old and going strong with Down syndrome and no dementia
2. Is yakult helpful in the treatment of irritable bowel syndrome?
3. Bisphenol A linked to metabolic syndrome in human tissue
4. UC Davis researchers define characteristics, treatment options for XXYY syndrome
5. Model for angelman syndrome developed by University of Texas at Austin biologists
6. Researcher helping to pioneer medical therapy for Fragile X Syndrome presents latest findings
7. The aorta is torn apart in the Marfan syndrome
8. Researchers discover gene for branchio-oculo-facial syndrome
9. Study suggests new way to screen infants for fetal alcohol syndrome
10. Effective ADHD treatment found for children with fragile X syndrome
11. Rare cancer-causing syndrome found, for the first time, in Singapore
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company") a biometric ... revised version of one of its first 30 second commercials will ... New York , Chicago , ... metro areas.    , , , , ... the cards in your wallet and keep your identity secure. ...
(Date:7/2/2015)... 2015 Research and Markets( ... "Next Generation Biometrics Market by Application, Technology, Function & ... their offering. The next generation biometrics market ... a CAGR of 17.9% between 2015 and 2020 ... the market. Safran SA ( France ...
(Date:6/30/2015)... 30, 2015 To bolster its efforts and commitment ... announced today the addition of two new team members. ... advisor and David Raviv will act as head ... Corp.,s commitment to providing the most secure solutions for the ... co-founded Layer 7 Technologies, a provider of security and management ...
Breaking Biology News(10 mins):Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 3HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3
... This release is available in French . ... and growing problem in hospitals and other health care facilities, ... developed in several decades. However, a large-scale, phase 3 trial ... antibiotic Fidaxomicin is superior to existing treatments, demonstrating a 45 ...
... Sputnik moment," President Obama emphasized the national need for ... State of the Union address last week: "We,ll invest ... technologyan investment that will strengthen our security, protect our ... President Obama specifically cited the need for research ...
... that five scientists with novel approaches to fighting cancer ... Innovation Award. The grant of $450,000 over three ... whose projects have the potential to significantly impact the ... The 2011 Damon Runyon-Rachleff Innovators are: Alexei ...
Cached Biology News:First new C. difficile drug in a generation superior to existing treatments: Researchers 2Damon Runyon-Rachleff Innovation Awards granted for pioneering ideas in cancer research 2Damon Runyon-Rachleff Innovation Awards granted for pioneering ideas in cancer research 3
(Date:7/30/2015)... , July 30, 2015  Discovery Laboratories, Inc. ... has received the second $1.0M tranche under a ... (SBIR) grant valued at up to $3.0 million ... KL4 surfactant as a potential medical countermeasure to ... Labs was awarded an initial $1.0 million under ...
(Date:7/29/2015)... 2015 Sanofi, a global ... second quarter of 2015. CEO Olivier Brandicourt ... performance in different businesses. Watch video ... Topics covered in the interview ... - Performance drivers - Diabetes ...
(Date:7/29/2015)... US-Australian drug discovery company, Novogen Limited (ASX: NRT; NASDAQ: ... progressing its ground-breaking technology platforms to Phase 1 clinical ... Company delivers the best value for shareholders. ... the Company currently had an extensive program of activities ... academic partnerships and initiatives, and he was working with ...
(Date:7/29/2015)... July 29, 2015  HealthSouth Corporation ... largest providers of post-acute healthcare services, offering both ... results of operations for the second quarter ended ... was characterized by strong volume growth in both ... EBITDA," said Jay Grinney, President and Chief Executive ...
Breaking Biology Technology:Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 2Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 3Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 3Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 4Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 5Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 6Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 7Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 8Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 9Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 10HealthSouth Reports Results for Second Quarter 2015 2HealthSouth Reports Results for Second Quarter 2015 3HealthSouth Reports Results for Second Quarter 2015 4HealthSouth Reports Results for Second Quarter 2015 5HealthSouth Reports Results for Second Quarter 2015 6HealthSouth Reports Results for Second Quarter 2015 7HealthSouth Reports Results for Second Quarter 2015 8HealthSouth Reports Results for Second Quarter 2015 9HealthSouth Reports Results for Second Quarter 2015 10HealthSouth Reports Results for Second Quarter 2015 11HealthSouth Reports Results for Second Quarter 2015 12HealthSouth Reports Results for Second Quarter 2015 13HealthSouth Reports Results for Second Quarter 2015 14HealthSouth Reports Results for Second Quarter 2015 15HealthSouth Reports Results for Second Quarter 2015 16HealthSouth Reports Results for Second Quarter 2015 17HealthSouth Reports Results for Second Quarter 2015 18HealthSouth Reports Results for Second Quarter 2015 19HealthSouth Reports Results for Second Quarter 2015 20HealthSouth Reports Results for Second Quarter 2015 21HealthSouth Reports Results for Second Quarter 2015 22HealthSouth Reports Results for Second Quarter 2015 23HealthSouth Reports Results for Second Quarter 2015 24HealthSouth Reports Results for Second Quarter 2015 25
... ... ... PRXL ), a leading global biopharmaceutical services,organization, today announced the ... technology organization. By combining,ClinPhone with Perceptive Informatics, PAREXEL,s wholly-owned technology,subsidiary, ...
... p.m. ET Today -, SUNNYVALE, Calif., Aug. 14 ... its fourth quarter,and fiscal year ended June 30, 2008. The ... million, or $0.18 per share, compared to a net loss ... of fiscal 2007., Total operating expenses were $4.8 million ...
... aerospace and ocean engineering at Virginia Tech, has received ... Junior Faculty Award. The award will support Philen,s research ... material and structural systems that have the unique ability ... these innovative materials will lead to new and exciting ...
Cached Biology Technology:PAREXEL Closes the Acquisition of ClinPhone 2PAREXEL Closes the Acquisition of ClinPhone 3PAREXEL Closes the Acquisition of ClinPhone 4PAREXEL Closes the Acquisition of ClinPhone 5Pharmacyclics Reports Fourth Quarter and Fiscal 2008 Financial Results 2Pharmacyclics Reports Fourth Quarter and Fiscal 2008 Financial Results 3Pharmacyclics Reports Fourth Quarter and Fiscal 2008 Financial Results 4Pharmacyclics Reports Fourth Quarter and Fiscal 2008 Financial Results 5Pharmacyclics Reports Fourth Quarter and Fiscal 2008 Financial Results 6
Our Histology, Immunohistochemistry and tissue arrays services include samples processing, different type of staning, histollogical stains, image analysis, tissue arrays, immunohistochemistry, etc....
Mouse polyclonal antibody to GRID2 - glutamate receptor, ionotropic, delta 2...
... pLivSelect is a direct antibiotic-based selection system ... on colony survival, eliminating the need for ... process provides close to 100% accuracy in ... platform for robot colony picking. This cloning ...
Mouse polyclonal antibody raised against a partial recombinant KCTD13. NCBI Entrez Gene ID = 253980...
Biology Products: